Corporate Profile

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. 

We believe that our approach is applicable to a broad range of diseases. We are primarily focused on applying our technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Our lead pulmonary candidate is being evaluated in a Phase 1/2 clinical trial as an inhaled treatment for cystic fibrosis. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize our proprietary lung delivery capabilities.

We are also pursuing an innovative alternative to conventional vaccines under a collaboration with Sanofi Pasteur — the development of mRNA vaccines for multiple infectious diseases, including SARS-CoV-2, the novel coronavirus responsible for the disease known as COVID-19. In addition, Translate Bio is pursuing discovery efforts in diseases that affect the liver, and our platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as oncology.

2020 Shareholder Letter

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.